ESMO 2022: Overall Survival Examined for Patients With Leptomeningeal Disease in Metastatic Melanoma
Immunotherapy and target therapy improved survival time with leptomeningeal disease, though prognosis still poor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.